Natco Pharma has signed an MoU with the University of Hyderabad to carry out advance research in the areas of pharmaceutical segment.
As per the agreement, the focus areas would be discovery of novel drugs, development of drug delivery systems viz., nano formulations of new chemical entities and biotechnological processes for specific products with potential commercial importance.
Natco and the varsity will promote cooperation in academic exchange, R & D collaborations, training and research in the areas of biotechnology, pharmacology, toxicology, pharmaceutical technology, and organising of national and international symposia, conferences, specialized exhibitions etc.
The agreement was signed by Chowdary V Nannapaneni, Chairman and Managing Director of Natco Pharma Ltd. and P Sardar Singh, Registrar of UoH.
The School has been working with Natco Pharma and in one of the projects has resulted in developing one of the molecules to Phase-II clinical trials for the treatment of chronic myeloid leukaemia. It has a faculty of 55 with 350 PhD and 60 Post Docs and latest research facilities.